Rate of adverse events excluding falls (per person year) · people with Parkinson's disease
Summary of findings for cholinesterase inhibitors may leads to higher rate of adverse events excluding falls (per person year) compared with placebo (low certainty).
1 finding from 1 review
Economic outcomes · people with Parkinson's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Falls · people with Parkinson's disease
Summary of findings for cholinesterase inhibitors may leads to lower rate of falls (falls per person‐year) compared with placebo (low certainty).
1 finding from 1 review
Number of people who experienced one or more falls · people with Parkinson's disease
1 finding from 1 review
Number of people sustaining one or more fall‐related fractures · people with Parkinson's disease
1 finding from 1 review
Pain resolution · people with SCD
1 finding from 1 review
Frequency of pain crises in the · people with SCD
Inhaled nitric oxide showed no clear difference in frequency of pain crises in the compared with placebo (low certainty).
2 findings from 1 review
Adverse events · people with SCD
1 finding from 1 review
Pain · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Physical function · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Quality of life · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Participant‐reported global assessment · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Radiographic joint changes · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Adverse events · Patients with osteoarthritis of the knee or hip
Summary of findings table ‐ Adjunctive therapies in addition to… showed no clear difference in adverse events compared with placebo adjunctive therapies (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Mean change in pain from baseline (0‐ to 10‐point scale, 0 is no pain) at 8–16 weeks · predominantly knee osteoarthritis
Antidepressant showed no clear difference in mean change in pain from baseline (0‐ to 10‐point scale, 0 is no… compared with placebo (high certainty).
1 finding from 1 review
At least 50% reduction in pain · predominantly knee osteoarthritis
Antidepressant leads to higher responder rate: ≥ 50% reduction in 24‐hour mean pain compared with placebo (high certainty).
1 finding from 1 review
Physical function · predominantly knee osteoarthritis
Antidepressant showed no clear difference in mean change in physical function from baseline (0–100 WOMAC Total… compared with placebo (high certainty).
1 finding from 1 review
Quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0 indicates perfect health) between 0 and 14 weeks · predominantly knee osteoarthritis
Antidepressant probably leads to higher quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0… compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants who withdrew due to adverse events between 0 and 14 weeks · predominantly knee osteoarthritis
Antidepressant probably leads to higher proportion of participants who withdrew due to adverse events… compared with placebo (moderate certainty).
1 finding from 1 review